Research Article
P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes
Table 2
Baseline characteristics after propensity matching.
| | Characteristics | Clopidogrel | Ticagrelor | | Clopidogrel | Prasugrel | | | (n = 1704) | (n = 568) | (n = 1503) | (n = 501) |
| | Demographics | | Age | 62.1 ± 10.8 | 61.3 ± 11.7 | 0.13 | 60.3 ± 10.3 | 58.1 ± 10.5 | <0.001 | | Female gender | 313 (18.4) | 130 (22.9) | 0.02 | 229 (15.2) | 97 (19.4) | 0.03 | | Race | | | 0.82 | | | 0.44 | | White | 1097 (64.4) | 378 (66.5) | | 944 (62.8) | 318 (63.5) | | | Black | 99 (5.8) | 20 (3.5) | | 85 (5.7) | 28 (5.6) | | | Asian | 319 (18.7) | 101 (17.8) | | 293 (19.5) | 89 (17.8) | | | Other/unknown | 189 (11.1) | 69 (12.2) | | 181 (12.0) | 66 (13.1) | | | Hispanic ethnicity | 213 (12.5) | 64 (11.3) | 0.44 | 190 (12.6) | 69 (13.8) | 0.51 | | Cardiovascular history | | Prior MI | 209 (12.3) | 86 (15.1) | 0.08 | 257 (17.1) | 117 (23.4) | 0.002 | | Prior CABG | 92 (5.4) | 30 (5.3) | 0.91 | 83 (5.5) | 30 (6.0) | 0.70 | | Cerebrovascular disease | 55 (3.2) | 25 (4.4) | 0.19 | 21 (1.4) | 7 (1.4) | 1.00 | | Peripheral vascular | 379 (22.2) | 137 (24.1) | 0.35 | 316 (21.0) | 105 (21.0) | 0.97 | | Disease | | Heart failure | 204 (12.0) | 80 (14.1) | 0.19 | 182 (12.1) | 76 (15.2) | 0.08 | | Atrial fibrillation | 66 (3.9) | 23 (4.0) | 0.85 | 57 (3.8) | 22 (4.4) | 0.55 | | Hyperlipidemia | 913 (53.6) | 305 (53.7) | 0.96 | 796 (53.0) | 281 (56.1) | 0.22 | | Hypertension | 1048 (61.5) | 358 (63.0) | 0.52 | 940 (62.5) | 321 (64.1) | 0.54 | | Diabetes | 435 (25.5) | 176 (31.0) | 0.01 | 381 (25.3) | 137 (27.3) | 0.38 | | Other risk factors | | Smoking | | | 0.52 | | | 0.87 | | Previous | 532 (31.2) | 166 (29.2) | | 493 (32.8) | 166 (33.1) | | | Current | 237 (13.9) | 88 (15.5) | | 272 (18.1) | 95 (19.0) | | | No/unknown | 935 (54.9) | 314 (55.3) | | 738 (49.1) | 240 (47.9) | | | Chronic kidney disease | 235 (13.8) | 86 (15.1) | 0.42 | 206 (13.7) | 74 (14.8) | 0.55 | | Chronic lung disease | 96 (5.6) | 44 (7.7) | 0.07 | 95 (6.3) | 36 (7.2) | 0.50 | | Dialysis | 28 (1.6) | 8 (1.4) | 0.70 | 24 (1.6) | 5 (1.0) | 0.33 | | Dyslipidemia | 1182 (69.4) | 401 (70.6) | 0.58 | 1063 (70.7) | 362 (72.3) | 0.51 | | Family history of premature CAD | 247 (14.5) | 87 (15.3) | 0.63 | 230 (15.3) | 93 (18.6) | 0.09 | | Liver disease | 117 (6.9) | 35 (6.2) | 0.56 | 92 (6.1) | 37 (7.4) | 0.32 | | Laboratory data | | Creatinine | 1.0 ± 0.8 | 1.1 ± 1.0 | 0.08 | 1.0 ± 0.9 | 1.0 ± 0.7 | 0.56 | | Hemoglobin | 14.0 ± 1.8 | 14.3 ± 1.8 | <0.001 | 14.0 ± 1.7 | 14.1 ± 1.8 | 0.15 | | Platelets | 220.3 ± 68.9 | 234.8 ± 65.3 | <0.001 | 223.0 ± 70.9 | 226.5 ± 79.9 | 0.41 | | Sodium | 138.6 ± 3.0 | 138.0 ± 3.0 | <0.001 | 138.7 ± 2.9 | 139.1 ± 3.2 | 0.01 | | WBC count | 9.0 ± 3.6 | 9.6 ± 3.1 | <0.001 | 8.9 ± 3.2 | 9.4 ± 3.4 | 0.01 | | Procedure details | | PCI indication | | | <0.001 | | | <0.001 | | NSTEMI/unstable angina | 1183 (69.4) | 285 (50.2) | | 1070 (71.2) | 297 (59.3) | | | STEMI | 521 (30.6) | 283 (49.8) | | 433 (28.8) | 204 (40.7) | | | Bare metal stent | 90 (5.3) | 8 (1.4) | <0.001 | 53 (3.5) | 19 (3.8) | 0.78 | | Drug eluting stent | 1557 (91.4) | 543 (95.6) | 0.001 | 1389 (92.4) | 469 (93.6) | 0.37 | | Thrombectomy | 128 (7.5) | 33 (5.8) | 0.17 | 96 (6.4) | 70 (14.0) | <0.001 | | Bifurcation lesion | 386 (22.7) | 54 (9.5) | <0.001 | 309 (20.6) | 99 (19.8) | 0.70 | | Lesion complexity | | | 0.08 | | | 0.18 | | High/C | 950 (55.8) | 293 (51.6) | | 809 (53.8) | 287 (57.3) | | | Nonhigh/non-C | 754 (44.2) | 275 (48.4) | | 694 (46.2) | 214 (42.7) | | | Previously treated lesion | 61 (3.6) | 25 (4.4) | 0.37 | 68 (4.5) | 53 (10.6) | <0.001 | | Vein graft PCI | 36 (2.1) | 12 (2.1) | 1.00 | 32 (2.1) | 12 (2.4) | 0.72 | | Cardiac arrest within 24 hours | 38 (2.2) | 12 (2.1) | 0.87 | 30 (2.0) | 17 (3.4) | 0.07 | | Cardiomyopathy or LV systolic dysfunction | 147 (8.6) | 18 (3.2) | <0.001 | 121 (8.1) | 36 (7.2) | 0.53 | | Cardiogenic shock within 24 hours | 29 (1.9) | 12 (3.2) | 0.11 | 20 (1.5) | 14 (2.9) | 0.04 | | Stress test | 391 (22.9) | 84 (14.8) | <0.001 | 313 (20.8) | 100 (20.0) | 0.68 | | Arterial access site | | | <0.001 | | | <0.001 | | Brachial | 4 (0.2) | 0 (0.0) | | 2 (0.1) | 1 (0.2) | | | Femoral | 872 (51.2) | 125 (22.0) | | 761 (50.6) | 335 (66.9) | | | Radial | 1 (0.1) | 1 (0.2) | | 2 (0.1) | 165 (32.9) | | | Other | 827 (48.5) | 442 (77.8) | | 738 (49.1) | 0 (0.0) | | | Fluoroscopy time | 16.8 ± 12.6 | 16.8 ± 11.9 | 0.95 | 16.6 ± 12.2 | 18.7 ± 15.0 | 0.004 | | Contrast volume (ml) | 181.6 ± 78.7 | 163.6 ± 67.1 | <0.001 | 181.0 ± 81.4 | 213.1 ± 99.3 | <0.001 | | Lesion length | 29.4 ± 20.7 | 31.2 ± 20.2 | 0.07 | 29.4 ± 21.2 | 31.1 ± 23.0 | 0.14 | | Risk score | | Precise DAPT score | 21.4 ± 16.2 | 18.6 ± 13.5 | <0.001 | 20.7 ± 15.7 | 19.3 ± 15.6 | 0.09 | | Medication use post PCI | | ACE inhibitors | 1121 (65.8) | 406 (71.5) | 0.01 | 1028 (68.4) | 351 (70.1) | 0.49 | | ARBs | 388 (22.8) | 139 (24.5) | 0.41 | 306 (20.4) | 101 (20.2) | 0.92 | | Oral anticoagulation | 100 (5.9) | 22 (3.9) | 0.07 | 90 (6.0) | 30 (6.0) | 1.00 | | Beta blockers | 1619 (95.0) | 542 (95.4) | 0.69 | 1436 (95.5) | 477 (95.2) | 0.76 | | Statins | 1673 (98.2) | 557 (98.1) | 0.86 | 1483 (98.7) | 490 (97.8) | 0.17 |
|
|
MI, myocardial infarction; CABG, coronary artery bypass graft; CAD, coronary artery disease; WBC, white blood cell; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; ACE inhibitors, angiotensin-converting enzyme inhibitors; and ARBs, angiotensin II receptor blockers.
|
